| Parameter | Source | Parameter uncertainty |
|---|---|---|
| PFS and overall survival | Mixed and indirect treatment comparison | Simulations from MTC |
| Proportion of patients discontinuing after first-line treatment | Review of clinical trials | Fixed |
| Health state utilities | Published literature (Best et al. 2010) | Beta distribution |
| Health state disutilities for toxicity | Published literature (using proxy estimates from metastatic breast cancer Lloyd et al. 2006) | Beta distribution |
| Toxicity rates | Review of clinical trials | Beta distribution |
| Toxicity management costs | National PbR tariff, NHS Reference Costs | Fixed |
| Drug cycles | Review of clinical trials | Gamma/uniform distribution |
| Drug unit costs | British National Formulary/NHS Commercial Medicines Unit | Fixed |
| Other healthcare resource use | Published literature (Guest et al. 2006) | Fixed |
| Other healthcare unit costs | National PbR tariff, NHS Reference Costs, PSSRU | Fixed |
From: 4, Management of metastatic disease
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.